Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy

Reuters10-24

Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy

Actinium Pharmaceuticals Inc. has announced new preclinical research results for ATNM-400, a first-in-class antibody radioconjugate armed with Actinium-225 (Ac-225), at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held October 23-25, 2025. The data demonstrated that ATNM-400, which targets a novel, non-PSMA antigen, showed superior efficacy and prolonged survival compared to existing PSMA-targeted radioligand therapies in models of low-PSMA and treatment-resistant prostate cancer. Notably, ATNM-400 remained effective even after androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy. The combination of ATNM-400 with the ARPI enzalutamide achieved complete tumor regression in 40% of treated animals, highlighting promising synergy. Additionally, Actinium is advancing ATNM-400 into non-small cell lung cancer (NSCLC), where it has shown the ability to overcome resistance to EGFR-TKI therapy in preclinical models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06069) on October 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577516661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577516661","market":"fut","top_or_hot":-1,"title":"Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced new preclinical research results for ATNM-400, a first-in-class antibody radioconjugate armed with Actinium-225 (Ac-225), at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held October 23-25, 2025. The data demonstrated that ATNM-400, which targets a novel, non-PSMA antigen, showed superior efficacy and prolonged survival compared to existing PSMA-targeted radioligand therapies in models of low-PSMA and treatment-resistant prostate cancer. Notably, ATNM-400 remained effective even after androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy. The combination of ATNM-400 with the ARPI enzalutamide achieved complete tumor regression in 40% of treated animals, highlighting promising synergy. Additionally, Actinium is advancing ATNM-400 into non-small cell lung cancer (NSCLC), where it has shown the ability to overcome resistance to EGFR-TKI therapy in preclinical models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06069) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced new preclinical research results for ATNM-400, a first-in-class antibody radioconjugate armed with Actinium-225 (Ac-225), at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held October 23-25, 2025. The data demonstrated that ATNM-400, which targets a novel, non-PSMA antigen, showed superior efficacy and prolonged survival compared to existing PSMA-targeted radioligand therapies in models of low-PSMA and treatment-resistant prostate cancer. Notably, ATNM-400 remained effective even after androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy. The combination of ATNM-400 with the ARPI enzalutamide achieved complete tumor regression in 40% of treated animals, highlighting promising synergy. Additionally, Actinium is advancing ATNM-400 into non-small cell lung cancer (NSCLC), where it has shown the ability to overcome resistance to EGFR-TKI therapy in preclinical models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06069) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL7ZG59S:1","article_id":"2577516661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577516661","pubTimestamp":1761309024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actinium Pharmaceuticals Inc. has announced new preclinical research results for ATNM-400, a first-in-class antibody radioconjugate armed with Actinium-225 , at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held October 23-25, 2025. The data demonstrated that ATNM-400, which targets a novel, non-PSMA antigen, showed superior efficacy and prolonged survival compared to existing PSMA-targeted radioligand therapies in models of low-PSMA and treatment-resistant prostate cancer. Notably, ATNM-400 remained effective even after androgen receptor pathway inhibitor  therapy and 177Lu-PSMA-617 therapy. The combination of ATNM-400 with the ARPI enzalutamide achieved complete tumor regression in 40% of treated animals, highlighting promising synergy. Additionally, Actinium is advancing ATNM-400 into non-small cell lung cancer , where it has shown the ability to overcome resistance to EGFR-TKI therapy in preclinical models.Disclaimer: This news brief was created by Public Technolog","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATNM":"Actinium Pharmaceuticals, Inc."},"translate_title":"Actinium Pharmaceuticals报告新型ATNM-400放射疗法的强大临床前疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":0.9},"content_text":"Actinium Pharmaceuticals Reports Potent Preclinical Efficacy for Novel ATNM-400 Radiotherapy\n    \n\n        Actinium Pharmaceuticals Inc. has announced new preclinical research results for ATNM-400, a first-in-class antibody radioconjugate armed with Actinium-225 (Ac-225), at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held October 23-25, 2025. The data demonstrated that ATNM-400, which targets a novel, non-PSMA antigen, showed superior efficacy and prolonged survival compared to existing PSMA-targeted radioligand therapies in models of low-PSMA and treatment-resistant prostate cancer. Notably, ATNM-400 remained effective even after androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy. The combination of ATNM-400 with the ARPI enzalutamide achieved complete tumor regression in 40% of treated animals, highlighting promising synergy. Additionally, Actinium is advancing ATNM-400 into non-small cell lung cancer (NSCLC), where it has shown the ability to overcome resistance to EGFR-TKI therapy in preclinical models.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY06069) on October 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577516661","isCrawlerRequest":true}